David Cory is a biopharmaceutical industry leader with 30 years of operational experience in public and private, large pharma and emerging stage biotechnology companies, with an extensive commercial background spanning multiple launches including global blockbuster products and targeted therapeutics for rare diseases, an established track record in the capital markets with over $1B+ raised and multiple companies which have successfully resulted in acquisition.
Mr. Cory was previously President and CEO, Director, and co-founder of Eiger BioPharmaceuticals, a commercial-stage biopharmaceutical company focused on the development of innovative therapies for serious, orphan diseases, and was responsible for negotiating multiple technology and product licenses from Stanford University, Merck, BMS, The Progeria Research Foundation, and Children’s Hospital of Philadelphia to build the pipeline, taking the company public, and obtaining the company’s first FDA and EMA product approvals. Previously, Mr. Cory was President and Chief Operating Officer of Prestwick Pharmaceuticals, an orphan CNS specialty pharmaceutical company, which was acquired by Biovail for $160 million. Earlier, Mr. Cory was a co-founder of CoTherix, an orphan pulmonary arterial hypertension company, which was acquired by Actelion for $425 million. Mr. Cory began his biotech career with the founding team at InterMune, focused on developing orphan products for idiopathic pulmonary fibrosis, where he was Senior Vice President and a key executive in the company IPO, in-licensing 4 products, and building and managing the company’s commercial organization. InterMune was acquired by Roche for $8 billion. Mr. Cory spent over a decade in large pharma in positions of increasing responsibilities in commercial operations at Glaxo, Glaxo Welcome, and Glaxo Smith Kline where he led teams in oncology, critical care, CNS, infectious disease, and respiratory therapeutic areas, and directed 10 newly approved pharmaceutical product launches. Mr. Cory began his pharmaceutical career at The Upjohn Company.
Mr. Cory earned a BS in Pharmacy from the University of Cincinnati, College of Pharmacy, was board certified in Pharmacy in the state of Ohio and holds an MBA from the University of Maryland.
Dr Stein received his medical degree and PhD, from the University of Witwatersrand Medical School in Johannesburg, South Africa. In 1972 he started the first Lipid Clinic in South Africa and described the very high gene frequency of FH in the Afrikaner population. After completing his specialist training in Medical Biochemistry at McMaster University Medical Center in Canada he spent 11 years as a full-time faculty member at the University of Cincinnati, Ohio, , achieving the rank of tenured Professor of Pathology and Laboratory Medicine and Associate Professor of Internal Medicine. In 1988, he moved his clinical and laboratory groups and formed the Metabolic and Atherosclerosis Research Center, specializing in clinical trials affecting lipid metabolism and Medical Research Laboratories (MRL) a global central lab for clinical trials. In 2002 MRL was acquired by Pharmaceutical Product Development Inc. In 2006 he rejoined Dr Troendle with whom he had founded Medpace and developed Medpace Reference Laboratories. He remained on the Medpace board until 2012.
Dr. Stein has had a number of appointments to the National Institutes of Health (NIH) since 1986, including the National Cholesterol Education Program. He served on the Data and Safety Advisory Board of the National Heart, Lung, and Blood Institute Program on Genetics in Hypertension from 1999-2003. In 2006 he was appointed to the FDA Clinical Chemistry and Clinical Toxicology Advisory Panel through 2010.
Over the last 35 years Dr. Stein has been an Advisory Board member for a number of pharmaceutical and biotech companies in the lipid area and a member of the board of directors of Xenon Pharmaceuticals, CymaBay and Medpace CRO.
Prior to joining LIB Therapeutics as Chief Medical Officer in 2020, Dr. Kallend was the CMO at The Medicines Company, overseeing the clinical development program for inclisiran, the siRNA for PCSK9, from inception through to NDA and MAA filings. From 2005 to 2012, he was the Global Clinical Leader and a Group Medical Director at Roche and was responsible for Phase 2 and Phase 3 clinical development of dalcetrapib and an advisor to other lipid programs in early- and late-stage development at Roche and Genentech. Prior to this, Dr. Kallend worked at AstraZeneca (UK) on the clinical development of rosuvastatin from Phase 2 to Phase 4 through post-approval. He was also involved in assessment of other therapies for the metabolism portfolio. Dr. Kallend began his career in the pharmaceutical industry as an International Clinical Research Physician working on imaging studies for Schering AG in Berlin, predominantly in the area of magnetic resonance imaging and contrast media diagnostics.
Dr. Kallend graduated from Kings College Hospital School of Medicine in London, and did his postgraduate training at the Royal Postgraduate Medical School, Hammersmith Hospital, London, finishing as a Research Fellow in the Department of Surgery.
Dr. Shekar Ganesa joined LIB Therapeutics in 2020 with 25+ years’ experience and manages the strategic/technical activities related to Process and Analytical development, Manufacturing, Quality, Supply chain, CMC regulatory initiatives at various CDMO’s and CRO’s for Lerodalcibep (LIB003).
Prior to LIB Therapeutics, Shekar has held several leadership roles at MassBiologics, Amgen and Genzyme-Sanofi leading cell line development/banking, upstream, downstream, formulation and analytical development activities for monoclonal antibodies, recombinant complex glycoproteins and gene therapy viral vector-based products leading to several successful INDs filings and BLAs approvals. Shekar continues to be a strong advocate of implementing Quality by Design (QbD) principles to understand, design and control critical product quality attributes while optimizing process performance.
Shekar has published numerous research articles and delivered keynote lectures at several national and international meetings. Dr. Shekar Ganesa received his Ph.D. in Biochemistry from Indiana State University, Terre Haute, IN and subsequently completed a post-doctoral fellowship in Biochemistry at the Worcester Foundation for Experimental Biology.
Rich, LIB Therapeutics' Chief Operating Officer, joined as a consultant in June 2024. He has over 30 years of experience in the pharmabio industry working for emerging and large companies in a variety of roles. Previously at Eiger BioPharmaceuticals, he served as Chief Regulatory Officer, overseeing the US, EU, and UK submissions and approvals of Zokinvy for the treatment of Progeria, and building the company’s global pharmacovigilance function.
Before Eiger, he was VP and GM of Bausch Health’s hospital and pain divisions, hospital/GPO contracting, and a national hospital and pain management sales teams. At Sprout Pharmaceuticals, prior to its acquisition by Bausch for $1B, he helped guide Addyi (flibanserin) to a positive advisory committee decision, built a comprehensive REMS program, led the build-out of Sprout’s commercial and PV infrastructure.
Earlier in his career he held several Vice President roles in the pharmabio and diagnostics industries and spent a decade at GSK, he held positions of increasing responsibility including, Director or Respiratory Operations and Senior Product Manager for Respiratory and Oncology products.
Rich holds two Bachelor of Art degrees, one in Marketing and the other in Communications from Michigan State University. He received his Master of Business Administration from the University of North Carolina, Chapel Hill.
Michael joins LIB as Chief Commercial Officer with over 30 years of experience in the biopharmaceutical industry, with a proven track record of driving strategic, financial, and operational success across a diverse range of therapeutic areas and organizational growth stages. His expertise spans strategic planning, operational excellence, and organizational leadership during critical transitions and transactions.
Michael was most recently General Manager for the US division of Medexus Pharmaceuticals, where he led all aspects of operations in support of its growing portfolio of small and large molecule therapeutics, including multiple licensing deals. Prior to Medexus, Michael was SVP, Commercial at Aptevo Therapeutics,where he led all commercial functions in support of a portfolio of orphan/rare disease biologics and immuno-oncology candidates. His leadership was instrumental in launching a novel biologic and successfully out-licensing a commercial portfolio. Earlier in his career, he held key commercial leadership roles at Cangene Corporation, Adolor Corporation, and AstraZeneca, where he was Brand Director for the successful launch of CRESTOR (rosuvastatin).
Mr. Adelman holds a Bachelor of Science in Finance from Northeastern University and a Master of Business Administration from New York University’s Stern School of Business.
Dr Choong brings more than 20 years of experience in start-up and operating roles in both private and publicly traded biotechnology companies from preclinical stage through clinical development, product approval and commercialization. Most recently she served as Chief Business Officer at Eiger BioPharmaceuticals. As a member of the founding team at Eiger, she transitioned from the bench into executive level operational roles over the next decade including clinical and regulatory development across multiple programs and therapeutic areas, investor relations, financing, business development and corporate communications. These efforts included the US and EU approval and launch of Zokinvy (lonafarnib), the first and only treatment approved to extend survival in Hutchinson-Gilford Progeria Syndrome, a rare fatal genetic condition in children. Dr Choong started her industry career at Sunesis Pharmaceuticals as a Principal Scientist in Lead Discovery Research.
Dr Choong earned a BS in Chemistry from the California Institute of Technology and a PhD in Chemistry from the University of California at Berkeley.
Mr. Stephen P. Ewald, J.D. serves as General Counsel, Corporate Secretary of the Company. Stephen P. Ewald joined Medpace as General Counsel and Corporate Secretary in June 2012.
Prior to joining Medpace, Mr. Ewald served as the Managing Director and Chief Legal Officer of Brevet Capital Management from May 2011 to June 2012. From May 2009 to May 2011, he was a Managing Director and Assistant General Counsel for Cantor Fitzgerald Securities/Cantor Fitzgerald & Co. Mr. Ewald was employed with Bank of America from 1999 to 2009, serving in various roles within the legal department and the Global Markets Group, including Managing Director and Chief Operating Officer of the Principal Capital Group, a proprietary investing group within Bank of America Securities.
Mr. Ewald has served as director for several private companies, including as a director of Symplmed Pharmaceuticals, LLC since 2013, as a director of LIB Therapeutics, LLC since 2016 and as a director of CinRx Pharma, LLC since 2016. Mr. Ewald received his Bachelor of Science in Political Sciences from the University of Cincinnati and his Juris Doctorate from the University of Cincinnati College of Law.
Dr. Troendle has been the Chief Executive Officer and Chairman of the Board of Directors of Medpace since he founded the Company in July 1992. Before founding Medpace, Dr. Troendle served as Assistant Director, Associate Director and Senior Associate Director from 1987 to 1992 at Sandoz (Novartis), where he was responsible for the clinical development of lipid altering agents.
From 1986 to 1987, Dr. Troendle worked as a Medical Review Officer in the Division of Metabolic and Endocrine Drug Products at the FDA. Dr. Troendle also has extensive experience serving as a director for a diverse group of public and private companies, including as a director of Coherus BioSciences, Inc. from 2012 to February 2018, as a director of Xenon Pharmaceuticals Inc. from 2007 to 2008, as a director of LIB Therapeutics, LLC since 2015, as a director of CinCor Pharma, Inc. from March 2018 to November 2021, and as a director of CinRx Pharma, LLC since 2015.
Dr. Troendle received his Medical Degree from the University of Maryland, School of Medicine and his Master of Business Administration from Boston University.
David Cory is a biopharmaceutical industry leader with 30 years of operational experience in public and private, large pharma and emerging stage biotechnology companies, with an extensive commercial background spanning multiple launches including global blockbuster products and targeted therapeutics for rare diseases, an established track record in the capital markets with over $1B+ raised and multiple companies which have successfully resulted in acquisition.
Mr. Cory was previously President and CEO, Director, and co-founder of Eiger BioPharmaceuticals, a commercial-stage biopharmaceutical company focused on the development of innovative therapies for serious, orphan diseases, and was responsible for negotiating multiple technology and product licenses from Stanford University, Merck, BMS, The Progeria Research Foundation, and Children’s Hospital of Philadelphia to build the pipeline, taking the company public, and obtaining the company’s first FDA and EMA product approvals. Previously, Mr. Cory was President and Chief Operating Officer of Prestwick Pharmaceuticals, an orphan CNS specialty pharmaceutical company, which was acquired by Biovail for $160 million. Earlier, Mr. Cory was a co-founder of CoTherix, an orphan pulmonary arterial hypertension company, which was acquired by Actelion for $425 million. Mr. Cory began his biotech career with the founding team at InterMune, focused on developing orphan products for idiopathic pulmonary fibrosis, where he was Senior Vice President and a key executive in the company IPO, in-licensing 4 products, and building and managing the company’s commercial organization. InterMune was acquired by Roche for $8 billion. Mr. Cory spent over a decade in large pharma in positions of increasing responsibilities in commercial operations at Glaxo, Glaxo Welcome, and Glaxo Smith Kline where he led teams in oncology, critical care, CNS, infectious disease, and respiratory therapeutic areas, and directed 10 newly approved pharmaceutical product launches. Mr. Cory began his pharmaceutical career at The Upjohn Company.
Mr. Cory earned a BS in Pharmacy from the University of Cincinnati, College of Pharmacy, was board certified in Pharmacy in the state of Ohio and holds an MBA from the University of Maryland.
Dr Stein received his medical degree and PhD, from the University of Witwatersrand Medical School in Johannesburg, South Africa. In 1972 he started the first Lipid Clinic in South Africa and described the very high gene frequency of FH in the Afrikaner population. After completing his specialist training in Medical Biochemistry at McMaster University Medical Center in Canada he spent 11 years as a full-time faculty member at the University of Cincinnati, Ohio, , achieving the rank of tenured Professor of Pathology and Laboratory Medicine and Associate Professor of Internal Medicine. In 1988, he moved his clinical and laboratory groups and formed the Metabolic and Atherosclerosis Research Center, specializing in clinical trials affecting lipid metabolism and Medical Research Laboratories (MRL) a global central lab for clinical trials. In 2002 MRL was acquired by Pharmaceutical Product Development Inc. In 2006 he rejoined Dr Troendle with whom he had founded Medpace and developed Medpace Reference Laboratories. He remained on the Medpace board until 2012.
Dr. Stein has had a number of appointments to the National Institutes of Health (NIH) since 1986, including the National Cholesterol Education Program. He served on the Data and Safety Advisory Board of the National Heart, Lung, and Blood Institute Program on Genetics in Hypertension from 1999-2003. In 2006 he was appointed to the FDA Clinical Chemistry and Clinical Toxicology Advisory Panel through 2010.
Over the last 35 years Dr. Stein has been an Advisory Board member for a number of pharmaceutical and biotech companies in the lipid area and a member of the board of directors of Xenon Pharmaceuticals, CymaBay and Medpace CRO.
Mr. Stephen P. Ewald, J.D. serves as General Counsel, Corporate Secretary of the Company. Stephen P. Ewald joined Medpace as General Counsel and Corporate Secretary in June 2012.
Prior to joining Medpace, Mr. Ewald served as the Managing Director and Chief Legal Officer of Brevet Capital Management from May 2011 to June 2012. From May 2009 to May 2011, he was a Managing Director and Assistant General Counsel for Cantor Fitzgerald Securities/Cantor Fitzgerald & Co. Mr. Ewald was employed with Bank of America from 1999 to 2009, serving in various roles within the legal department and the Global Markets Group, including Managing Director and Chief Operating Officer of the Principal Capital Group, a proprietary investing group within Bank of America Securities.
Mr. Ewald has served as director for several private companies, including as a director of Symplmed Pharmaceuticals, LLC since 2013, as a director of LIB Therapeutics, LLC since 2016 and as a director of CinRx Pharma, LLC since 2016. Mr. Ewald received his Bachelor of Science in Political Sciences from the University of Cincinnati and his Juris Doctorate from the University of Cincinnati College of Law.
Jesse J. Geiger joined Medpace in October 2007 as Corporate Controller, and he was appointed Chief Financial Officer in March 2011. Mr. Geiger became Chief Operating Officer, Laboratory Operations in November 2014. Mr. Geiger was appointed to the position of President on August 1, 2021. Prior to joining Medpace, Mr. Geiger worked for SENCORP from 2004 to 2007 as the Corporate Controller and Manager of Financial Planning and Analysis.
Prior to SENCORP, Mr. Geiger served as the Director of Capital Markets for Cincinnati Bell from 2002 to 2004. Mr. Geiger started his career in the audit practice at Arthur Andersen LLP. Mr. Geiger has served as a director for several private companies, including as a director of LIB Therapeutics, LLC since 2015 and as a director of CinRx Pharma, LLC since 2015. Mr. Geiger received his Bachelor of Business Administration in Accounting from the University of Cincinnati and is a Certified Public Accountant (Inactive).
Dr Stoner received her M.D. from the Albert Einstein College of Medicine, her M.S. in Chemistry from SUNY at Stony Brook and her B.S. in Chemistry from Ottawa University, KS and prior to joining the pharmaceutical industry, she was an Assistant Professor of Pediatrics at Cornell University Medical College. At Merck Research Laboratories she rose to Senior Vice President of Global Clinical Development Operations with responsibility for clinical development activities in more than 40 countries. Liz also oversaw the clinical development activities of its Japanese subsidiary and played a leading role in Merck/Schering Plough Joint Venture’s development of Vytorin and Zetia, blockbuster cholesterol lowering drugs.
After leaving Merck Liz joined MPM and has held several leadership roles at MPM portfolio companies including interim CEO of Semma Therapeutics; founder, CMO and Chief Development Officer (CDO) of Rhythm and the CDO of Vascular Pharmaceuticals. She also served in clinical and advisory roles at Clinical Ink, Potenza Therapeutics, Solasia and TriNetX. Liz is a member of the Cures Acceleration Network Review Board of the National Center for Advisory Translations Sciences of the NIH to represent viewpoints of drug development and venture capital professionals regarding the discovery and development of therapeutics, diagnostics and devices.
Dr Stoner joined LIB Therapeutics board in 2016.
Professor Derick Raal is Professor and Head of the Division of Endocrinology and Metabolism and Director, Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences at the University of the Witwatersrand, Johannesburg, South Africa. After obtaining his MBBCh degree cum laude in 1981, he obtained his Master of Medicine and his PhD in 2000 and his Doctor of Science in 2022. Professor Raal has received numerous postgraduate awards including the TH Bothwell Research Prize, the FJ Milne award, and the University of the Witwatersrand Vice Chancellor’s Research Award in 2015.
He is a NRF A-rated scientist, was recognized as a Web of Science highly cited researcher for 2021, and has authored or co-authored over 350 original articles and book chapters and has reviewed for several international journals including the New England Journal of Medicine, the Lancet, Circulation, and Atherosclerosis. He is a committee member of the homozygous FH International Collaborators registry as well as a member of the steering committee of the European Atherosclerosis Society FH Studies Collaboration (EAS FHSC). He is on the Editorial Board of Atherosclerosis and is a board member of the International Atherosclerosis Society.
Professor Raal is particularly interested in lipids and lipid disorders and has been integrally involved in the management of familial dyslipidaemia, particularly heterozygous and homozygous familial hypercholesterolaemia (FH). The major focus of his research remains the clinical, biochemical, genetic and therapeutic management of this condition and he continues to conduct studies with novel therapies such as PCSK9-inhibitors and ANGPTL3-inhibitors in this patient group.
Deutsches Herzzentrum München, Technische Universität München, Munich, Germany
Wolfgang Koenig is a Professor of Medicine/Cardiology. A former Director of the WHO-MONICA Augsburg Myocardial Infarction Registry, he has held multiple clinical positions at the University of Ulm Medical Center. In April 2015 he joined the Deutsches Herzzentrum München, where he is the Head of the Cardiometabolic Unit.
Professor Koenig serves on the steering committee of multiple large clinical trials. His research includes the molecular basis of atherothrombogenesis, and the clinical epidemiology of cardiovascular disorders, focusing on the identification and evaluation of new biomarkers for cardiometabolic diseases.
He has published more than 1000 papers in peer-reviewed journals. Between 2008 and 2017, he ranked sixteenth among the most frequently cited German speaking researchers in cardiovascular disease and has an H-Index of 115. He is a member of the Editorial Board of “Clinical Chemistry” and Associate Editor of “Cardiovascular Drugs and Therapy”.
In 2014 he was given the Rudolf Schönheimer Award from the German Atherosclerosis Society, in 2019 he received the degree of Adjunct Professor from the Medical University of Vienna and in 2020 he was awarded the Paul Morawitz prize from the German Cardiac Society.
Professor Kayikcioglu is Director of Lipids and Prevention Clinic, Department of Cardiology, Ege University School of Medicine, Izmir, Turkey. She is also Director of Premature Myocardial Infarction Clinic and Consultant Cardiologist for the Pulmonary Hypertension and Rare Disease Clinic.
Prof Kayikcioglu obtained her MD at Ege University School of Medicine, where she also completed her post graduate training in Internal Medicine and Cardiology.
Prof Kayikcioglu is active in a number of national and international societies including the National Cardiovascular (CV) Disease Prevention European Society of Cardiology (ESC) serving as Coordinator for Turkey between 2009-2022. She has been the deputy ambassador of MENA and India Regions of ESC since 2018 and has been a member of ESC-EORP Oversight Committee and ESC Global Affairs Committee since 2018.
Prof Kayikcioglu has been the Associate Editor of Archives of the Turkish Society of Cardiology since 2016 and chairs the national registries on CV and Rare Diseases including familial hypercholesterolemia (A-HIT 1 and A-HIT 2); the registry of premature myocardial infarction in Turkey (A-HIT 3) and ARTEMIS (registry of peri-partum CMP) and is the national coordinator for EAS of FHSC (Familial Hypercholesterolemia Studies Collaboration). She actively collaborates with the Turkish Ministry of Health on several CV prevention projects.
Prof Kayikcioglu has H-index of 34, i10-Index of 93 and has published more than 180 publications in peer reviewed journals.
.jpg)
The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.
A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!
Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.